

# Sleep Apnea and Obesity

Vikas Jain MD FAASM

Dream Center for Sleep and Circadian Sciences


Frisco TX

# Case

- A 42 year old patient with BMI of 42 presents to the sleep clinic for a bariatric surgery consultation. The patient does not feel that they are symptomatic and “just needs to get this done for surgery” and is going to “lose weight anyways” after surgery.
- Concerning?
- Typical?

# Objectives

- 1. Highlight the importance of sleep in cardiometabolic health and obesity management.
- 2. Outline screening, diagnosis, and treatment of sleep apnea
- 3. Discuss strategies to improve sleep duration and quality.



Obesity in turn raises the risk of morbidity from hypertension, hyperlipidemia, type 2 diabetes mellitus, coronary heart disease (CHD), stroke, gallbladder disease, osteoarthritis, sleep apnea and respiratory problems, and some cancers.

# Why Is Sleep Important?

- We Spend 1/3 of our lives asleep!
- “If sleep doesn’t serve an absolutely vital function, it is the biggest mistake evolution ever made.
- ALLAN RECHTSCHAFFEN

# What is the recommended amount of sleep?

- American Academy of Sleep Medicine and Sleep Research society 2015 Consensus Panel
  - Panel 16 experts, 12-month process
  - Reviewed 5,314 articles
  - Oxford grading system, RAND Appropriateness
- Conclusions:
  - **≥ 7 hours sleep per night on regular basis are required for optimal health among adults 18-60 yrs.**
    - Weight gain, obesity, diabetes, hypertension, heart disease, stroke, depression, death.
    - Impaired immune function, increased pain, impaired performance, increased errors, accidents
  - **> 9 hours sleep per night on regular basis may be appropriate for young adults, those recovering from sleep debt or individuals with disease.**
  - Uncertain if > 9 hr. in others is associated with risk
- \*Sleep recommendations for children/adolescents
  - Infants (4-12 mo.) 12-16 h.
  - Toddlers (1-2 y.) 11-14 h.
  - Preschoolers (3-5 y.) 11-13 h.
  - Children (6-12 y.) 9-12 h.
  - Teenagers (13-18 y) 8-10 h.
  - Regularly sleeping more than recommended amounts may be associated with adverse health outcomes

# HEALTH RISKS OF NOT SLEEPING



7-9 HRS

THE RECOMMENDED AMOUNT; IMPROVES HEALTH AND DAILY ALERTNESS

5-7 HRS

THE AVERAGE AMOUNT THAT AMERICAN ADULTS SLEEP EACH NIGHT

0-5 HRS

PUTS YOU AT HIGH RISK FOR A NUMBER OF HEALTH PROBLEMS:

2.5X HIGHER RISK FOR DIABETES



45% HIGHER RISK FOR HEART ATTACK



12% HIGHER RISK OF DEATH UNDER ANY CIRCUMSTANCE





# Prevalence of Sleep Loss


- It is estimated that at least 36% of the US population suffers from sleep loss
- 1/3 of young adults secondary to chronic partial sleep deprivation
- 7% of Adults secondary to sleep disorders
- 2% of Adults secondary to shift work

# Daytime Sleepiness

- Reducing total sleep time in normal young adults by 1-1.5 hours can decrease objective alertness by up to 33%

# Prevalence<sup>†</sup> of Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2011

<sup>†</sup> Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be compared to prevalence estimates before 2011.




\*Sample size <50, the relative standard error (dividing the standard error by the prevalence)  $\geq 30\%$ , or no data in a specific year.





# Prevalence<sup>1</sup> of Obesity Based on Self-Reported Weight and Height Among US Adults by State and Territory, BRFSS, 2022


<sup>1</sup> Prevalence  
com



\*Sample size <50, the relative standard error (dividing the standard error by the prevalence)  $\geq 30\%$ , or no data in a specific year.



# Sleep Duration and Obesity



Very short sleepers (<5 hours) twice as likely to be obese.  
Short sleepers (5–6 hours) 57% greater odds of being obese.

# Obesity, Sleep, and Metabolic Hormones:

Obesity, and changes in sleep parameters and/or sleep disorders (e.g., sleep apnea) may impact metabolic hormones.

# Leptin and Ghrelin

## **Leptin:**

A satiety hormone produced primarily by subcutaneous white adipose tissue. It interacts with receptors in the hypothalamus to inhibit eating and control body weight and fat distribution.

## **Ghrelin:**

A peptide, produced predominantly by the stomach, stimulates appetite.



# Leptin and Ghrelin

## **Leptin:**


The satiety hormone leptin is largely dependent on meal intake and therefore shows a morning minimum and increasing levels throughout the daytime culminating in a nocturnal maximum.

## **Ghrelin:**

During the daytime, the levels increase in anticipation of a meal and then decrease after meal ingestion.


The hunger hormone ghrelin increases initially but then decreases during the second part of the night.

# Ghrelin, Leptin, and Obesity



Ghrelin levels are decreased in obesity.  
Leptin levels are increased in obesity.

# Ghrelin, Leptin, and Sleep Duration



# Short Sleep and Obesity:

- Influences weight through effects on appetite.
- Causes excessive daytime sleepiness and, therefore, lead to decreased physical activity, and a decrease in energy expenditure.
- Causes increased energy intake to counter excessive daytime sleepiness.
- Provides more time to eat.

# Sleep Restriction, Slow-Wave Sleep, and Glucose Regulation:

- Poor sleep quality associated with increase risk of type 2 diabetes.
- Sleep restriction significantly impairs glucose tolerance.
- All-night selective suppression of SWS led to marked decreases in insulin sensitivity without adequate compensatory increase in insulin release.
- Reduced sleep quality (e.g., low levels of SWS) may contribute to increased risk of diabetes.

# Obstructive Sleep Apnea

- Age
- **Obesity (50-80% Prevalence in this population) – Our Patient Case**
- Male Gender
- Anatomic Abnormalities
- Hypothyroidism
- Medications, Alcohol

# Obstructive Sleep Apnea - Symptoms

- Excessive daytime sleepiness
- Awakening during the night
  - Gasping/choking
- Snoring
- Associated with DM, HTN, stroke, A. Fib, CHF
- Associated with Obesity, Large Neck

# OSA- Evaluation


- Symptoms – Snoring, EDS, Gasping/Choking, ask Bed Partner!
- HEENT exam
  - Deviated septum
  - Nasal polyps
  - Micrognathia, Retrognathia
  - Short Thick Neck (>16 in women, >17 in men)
- Cardiovascular Exam
- Medications
- Think about Patient populations

Blythe J, Doghramji PP, Jungquist CR, Landau MB, Valerio TD, Ancoli-Israel S, et al.  
Screening & treating patients with sleep/wake disorders. JAAPA. 2009 Dec;Suppl Sleep:1-17



# OSA- Evaluation


- Mallampati Score
  - Class I
    - Full visibility of tonsils
  - Class II
    - Upper portion of tonsils/uvula
  - Class III
    - Soft/hard palate visible
  - Class IV
    - Only hard palate visible



# What can you tell patients about OSA and Obesity?

- Up to 75 % of individuals with OSA are obese.
- > 70 % of severe obese (i.e., grade 2) have OSA.
- At least 70 % of obese women with polycystic ovarian syndrome (PCOS) have OSA.
- Over 86 % of obese patients with type 2 diabetes have OSA.

# Prevalence of OSA



# Types of Sleep Studies

- Home Sleep Study (CPT 95806, 95800, 95801)
  - Only for OSA
  - Due to the known rate of false negative PM tests, attended PSG should be performed in cases where PM is technically inadequate or fails to establish the diagnosis of OSA
- Overnight Attended PSG (CPT 95810, 95811)
  - Diagnostic PSG/Split Night PSG
  - Used to evaluate sleep disorders such as RBD, PLMD, OSA (patients with conditions where HST not indicated), CSA

# Treatment Options

- PAP Therapy
- Surgery
- Dental Appliances
- **Weight Loss/Behavioral Modifications**

Obesity is a Major, Modifiable  
Risk Factor for OSA

## What can you tell patients about weight changes and OSA?

- 10 % decrease in weight correlates with an AHI reduction of 26 %.
- 20 % decrease in weight correlates with an AHI reduction of 48 %.
- 10 % increase in BMI associated with an increase in AHI of 32 %.


# Obesity Interventions and Impact on OSA

- Lifestyle
- GLP-1 (liraglutide/tirzepatide)
- Bariatric Surgery



# SLEEP AHEAD 2021 - AJRCCM

- 10 year follow up PSG of 134/264 adults with overweight/obesity, DM2 and OSA randomized to intensive lifestyle intervention (ILI) vs diabetes support and education (DSE)
- PSG performed at 1,2, 4, and 10 years (caveat substantial number of PSG not obtained at f/u) – common issue in practice!



**Figure 4.** Percentage of ILI (solid bars) and DSE (open bars) participants without OSA and with mild, moderate, and severe OSA at 10 years compared with their OSA severity at baseline. For definition of abbreviations, see Figure 3.

Am J Respir Crit Care Med, 2021

<https://www.atsjournals.org/doi/abs/10.1164/rccm.201912-2511OC>

Published in: Samuel T. Kuna; David M. Reboussin; Elsa S. Strotmeyer; Richard P. Millman; Gary Zammit; Michael P. Walkup; Thomas A. Wadden; Rena R. Wing; F. Xavier Pi-Sunyer; Adam P. Spira; Gary D. Foster; Published in: Jon Freeman; Jennifer Patricio; Andrea Sifferman; Brian McGuckin; Stephanie Krauthamer-Ewing; Mary Jones-Parker; Matthew Anastasi; Beth Staley; Liz Roben; Marie Kearns; Caitlin Egan; Alexis Wojtanowski; Nida Cassim; Valerie Darcey; Sakhena Hin; Stephanie Vander Veur; *Am J Respir Crit Care Med* 203221-229.

DOI: 10.1164/rccm.201912-2511OC

Copyright © 2021 by the American Thoracic Society

One PowerPoint slide of each figure may be downloaded and used for educational not promotional purposes by an author for slide presentations only. The ATS citation line must appear in at least 10-point type on all figures in all presentations. Pharmaceutical and Medical Education companies must request permission to download and use slides, and authors and/or publishing companies using the slides for new article creations for books or journals must apply for permission. For permission requests, please contact the Publisher at [dgern@thoracic.org](mailto:dgern@thoracic.org) or 212-315-6441.


AOM

# Trial Design: SCALE Sleep Apnoea

## Effect of Liraglutide 3.0 mg on Obstructive Sleep Apnoea Severity

### 359 participants:

- BMI  $\geq 30$  kg/m<sup>2</sup>
- Stable BW
- 18–64 years
- Moderate or severe OSA
- No CPAP



### Trial information:

- June 2012 to June 2013
- Randomised controlled double-blind study
- 40 sites in the US and Canada

### Trial objective:

- Efficacy of liraglutide 3.0 mg in reducing severity of OSA vs. placebo in obese participants with moderate/severe OSA

### Key endpoints:

- Primary: Change in AHI from baseline to week 32
- Secondary: Sleep parameters, body weight measurements, glycaemic parameters, cardiometabolic risk factors, patient-reported outcomes


# Baseline Characteristics

	Liraglutide 3.0 mg N=180		Placebo N=179	
	n	(%)	n	(%)
Completed	134	74.4	142	79.3
Mean AHI (events/h)	49.0		49.3	
Moderate OSA	60	(33.3)	58	(32.4)
Severe OSA	120	(66.7)	121	(67.6)
Mean age (years)	48.6		48.4	
Gender (female %)		(28.3)		(27.9)
Mean body weight (kg)	116.5		118.7	
Mean BMI (kg/m <sup>2</sup> )	38.9		39.4	
HbA <sub>1c</sub> (%)	5.7		5.6	
SBP (mmHg)	125.8		127.1	
Dyslipidaemia	65	(36.1)	55	(30.7)
Hypertension	75	(41.7)	77	(43.0)
Prediabetes	115	(63.9)	112	(62.6)

# Change in AHI (Events/h)

## 0–32 Weeks


Mean baseline AHI: 49.2 events/h



# Change in Body Weight (%)

## 0–32 Weeks

Mean baseline weight: 118 kg



# SCALE Sleep Apnoea

## Summary

- Liraglutide 3.0 mg, as an adjunct to diet and exercise, produced significantly greater reductions in AHI and body weight than placebo
- Safety profile was consistent with other trials in the liraglutide 3.0 mg phase 3 programme
  - Gastrointestinal AEs were the most commonly reported AEs; they were mostly mild or moderate in severity and transient
- SURMOUNT TRIAL UNDERWAY WITH TIRZEPATIDE



## Bariatric Surgery (Our Case)

- Several studies
- Nastalek et al – 44 patients treated with Bariatric Surgery (31 sleeve gastrectomy, 13 RYGB)
  - Only 16% with normalization of AHI, majority with stabilization or 41% with decrease in severity
- Lettieri et al – 24 patients evaluated with PSG before and 1 year following bariatric surgery
  - Only 1 patient with resolution of OSA (4%) with majority 71% still having moderate to severe disease

# General Sleep Tips and Strategies

# Sleep Disruption

- **Medications**

- Caffeine/Energy Drinks
- Nicotine
- Alcohol

- **Medical Conditions**

- Anxiety/Depression
- Sleep Disorder
- Menopause

- **Lifestyle**

- Large meals
- Vigorous Exercise

- **Environment**

- Cell Phone
- TV
- Computer

# Sleep Tips

The Single Most Effective thing you can do to reset your brain and body health is....

**GET A GOOD NIGHT SLEEP**

# Sleep Tips

- Regular Wake Time and Bed Time
- Keep your bedroom cool
- Keep your bedroom dark
- Keep your bedroom quiet
- Keep media and technology out of the bedroom
- Make the bedroom a haven
- Avoid alcohol, nicotine, caffeine (stop by 2pm or earlier)
- Get out of bed, go to another room, do something relaxing until you are sleepy and then GO BACK TO BED (not couch!)

# Sleep Hacks

- Before you can hack, track!
  - Consider using your phone, wearable, etc to monitor your sleep duration over a period of time
- Light control – try to limit light close to bedtime especially light within the blue spectrum
  - F-lux – for electronic devices
  - “NightShift” mode for Iphone
  - Light bulbs without blue light

# CME Question 1

- A 42 year old patient with BMI of 36 is diagnosed with Severe Obstructive Sleep Apnea with an AHI of 52. You advised CPAP therapy and also recommend initiating a GLP-1 to help with weight loss. You counsel the patient that a 10% reduction in weight is expected to correlate with an AHI reduction of:
  - A: 15%
  - B: 26%
  - C: 30%
  - D: 36%

Sleep Well!

